Zolgensma (onasemnogene abeparvovec), the ultra-high-priced ‘one-shot treatment’ that succeeded in receiving reimbursement in Korea in May this year, will start fulfilling the terms of its risk-sharing agreements (RSA) contract.

If the drug was administered at the time its reimbursement was approved in Korea, the medical institutions that administered Zolgensma would need to prepare a report on the effectiveness of the drug every 6 months and submit it to the Health Insurance Review and Assessment Service for 5 years.

HIRA’s New Drug Performance Management Division issued a notice to the hospital community that contains the ‘Operation Plan for the Performance Management of Zolgensma